$CERS

Jayaraman Vivek K sold $50K of CERS

Jayaraman Vivek K (Chief Operating Officer) sold 16,667 shares of CERUS CORP (CERS) at $3.00 on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jayaraman Vivek K
Published Jun 2, 2026, 11:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CERS
Neutral
medium confidence
Mentioned
$CERS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The disclosure provides a datapoint on insider activity but does not introduce new company fundamentals; 10b5-1 status suggests the trade was pre-planned.

02

Market read

Traders may adjust short-term sentiment/positioning around insider-selling headlines, but the 10b5-1 framing limits conviction.

03

What to watch

Check for other contemporaneous insider buys/sells and whether the officer’s remaining holdings or future scheduled trades change the net insider posture.

Relevance 6/10Novelty 6/10Timing: Disclosure filed June 2, covering a May 29 sale.

Background

The article is an SEC Form 4 insider transaction disclosure for Cerus Corp (CERS).

Company-level read

Ticker impact

$CERSNeutralMedium confidence
Context

Cerus Corp COO Jayaraman Vivek K sold 16,667 shares in an open-market transaction under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Small, short-lived negative-to-neutral bias possible around the disclosure; limited follow-through expected absent other catalysts.

Evidence & confidence

The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, reducing interpretive weight versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst indicated.

None indicated.

None indicated.

Counterpoint

Because the sale is 10b5-1, it may reflect planned liquidity needs rather than bearish expectations; the market may overreact to the headline.

Key entities

  • CERUS CORP

    Subject of the Form 4 insider transaction; COO sold shares under a 10b5-1 plan.

  • Jayaraman Vivek K

    Chief Operating Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.